Keywords: phynova, initiates, ph, iia, trial, pyn17, uk-based
Phynova initiates Ph IIa US trial of PYN17
Article | 04 June 2007
UK-based Phynova , a developer of prescription pharmaceuticals derived from Chinese botanical medicines, has commenced a Phase IIa US trial with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
